Alpha thalassaemia, a genetic blood disorder affecting oxygen transport in the body, requires careful management ranging from simple monitoring to complex medical interventions depending on its severity.

How Treatment Approaches Vary with Disease Severity

The treatment of alpha thalassaemia depends heavily on which form of the condition a person has and how severely it affects their body’s ability to produce hemoglobin, the protein in red blood cells that carries oxygen throughout the body. For many people with milder forms of alpha thalassaemia, treatment may not be necessary at all, while those with more severe forms may require lifelong medical care to manage serious complications^[1].

The goals of treatment in alpha thalassaemia focus on maintaining adequate levels of healthy red blood cells, preventing complications from the disease itself or from treatments like blood transfusions, and supporting normal growth and development, particularly in children. Medical teams work to balance the need for intervention with quality of life, aiming to help patients live as normally as possible while managing the medical challenges that come with more severe forms of the condition^[2].

Understanding that alpha thalassaemia exists on a spectrum is crucial for treatment planning. People who are silent carriers with only one affected gene typically experience no symptoms and require no treatment. Those with two affected genes, known as alpha thalassemia trait or minor, may have mild anemia (a shortage of red blood cells) but usually live normal lives without medical intervention. However, individuals with three affected genes, called Hemoglobin H disease, often need ongoing medical care, while those with all four genes affected, known as alpha thalassemia major or Hb Bart syndrome, face the most serious medical challenges^[3].

Standard Treatment Approaches for Alpha Thalassaemia

Management of Mild Forms

For people with alpha thalassaemia trait or silent carrier status, standard medical guidance emphasizes that specific treatment is generally not required. These individuals should avoid unnecessary iron supplementation, as their bodies do not lack iron—the problem lies in how their red blood cells are formed, not in iron deficiency. Taking iron supplements when they are not needed can lead to harmful iron buildup in the body^[9].

Healthcare providers recommend that people with mild forms of alpha thalassaemia maintain regular health checkups and inform their doctors about their condition before any medical procedures. This is particularly important for genetic counseling, especially when planning to have children, as both parents’ genetic status determines the risk of having a child with more severe forms of the disease^[5].

Blood Transfusions for Moderate to Severe Disease

Blood transfusions represent the cornerstone of treatment for people with Hemoglobin H disease and alpha thalassemia major. During a blood transfusion, healthy red blood cells from a donor are given to the patient through an intravenous line (a small tube inserted into a vein). This procedure typically takes between one and four hours to complete^[10].

The frequency of blood transfusions varies according to disease severity. People with Hemoglobin H disease may need transfusions only occasionally, particularly during times when the body is under stress such as during infections, pregnancy, or after surgery. In contrast, individuals with alpha thalassemia major who survive past birth require regular transfusions every three to four weeks throughout their lives to maintain hemoglobin levels above 9.5 grams per deciliter and support normal growth and development^[4][12].

These regular transfusions help prevent the severe anemia that would otherwise cause extreme fatigue, weakness, poor growth, and damage to organs including the heart and liver. By maintaining adequate hemoglobin levels, transfusions enable patients to carry out daily activities and reduce the risk of serious complications. However, the need for lifelong transfusions brings its own challenges, particularly the accumulation of excess iron in the body^[11].

Iron Chelation Therapy

Iron chelation therapy is a critical component of treatment for anyone receiving regular blood transfusions. The hemoglobin in red blood cells contains iron, and over time, repeated transfusions cause iron to build up to dangerous levels in the body. This iron overload can damage the heart, liver, and hormone-producing glands, leading to serious health problems and even death if left untreated^[10].

Three main medicines are used to remove excess iron from the body. Deferasirox is taken as a pill once daily, making it convenient for patients. Common side effects include nausea, vomiting, diarrhea, abdominal pain, and skin rashes. Deferoxamine is administered through an injection under the skin, typically using a small pump over eight to twelve hours, usually while the patient sleeps. This medication can cause pain at the injection site, hearing problems, and vision changes. Deferiprone is taken as a pill three times daily and may cause nausea, vomiting, and changes in blood cell counts^[10].

The choice of chelation therapy depends on several factors including the patient’s age, the severity of iron overload, other medical conditions, and personal preferences regarding the method of administration. Healthcare teams monitor iron levels regularly through blood tests measuring ferritin (a protein that stores iron) and sometimes through specialized imaging studies that can detect iron deposits in organs. Adjustments to the chelation regimen are made based on these results to ensure iron levels remain in a safe range^[11].

Folic Acid Supplementation

Many patients with Hemoglobin H disease benefit from folic acid supplementation, a B vitamin that helps the body produce red blood cells. Because people with more severe forms of alpha thalassaemia have an increased breakdown of red blood cells (a process called hemolysis), their bone marrow works overtime trying to produce new ones. This increased activity means the body uses up folic acid more quickly than normal^[9].

Folic acid supplementation is usually prescribed alongside other treatments and helps support the bone marrow’s ability to make new red blood cells. The typical dose and duration of folic acid therapy are determined by the healthcare team based on blood test results showing the patient’s red blood cell production rate and folic acid levels^[11].

Surgical Interventions

Some patients with alpha thalassaemia may require surgical removal of the spleen, a procedure called splenectomy. The spleen normally filters old and damaged red blood cells from circulation. In people with thalassaemia, the spleen can become enlarged because it works harder to remove the abnormally shaped red blood cells characteristic of the disease. An enlarged spleen may trap too many red blood cells, worsening anemia, or cause pain and discomfort. However, splenectomy is considered only in selected cases and is not routinely performed^[9].

After splenectomy, patients face an increased risk of serious infections, particularly from certain types of bacteria. To protect against this risk, individuals who have had their spleen removed must receive specific vaccines before the surgery if possible, including vaccines against Haemophilus influenzae type b, pneumococcal bacteria, and meningococcal bacteria. They may also need to take daily antibiotics and must be vigilant about seeking immediate medical care if they develop fever or other signs of infection^[14].

Innovative Treatments Being Studied in Clinical Trials

Gene Therapy Approaches

One of the most promising developments in alpha thalassaemia treatment involves gene therapy, an approach that aims to correct the underlying genetic problem causing the disease. In January 2024, the United States Food and Drug Administration approved a gene therapy called CASGEVY™ (also known as exagamglogene autotemcel or exa-cel) for the treatment of transfusion-dependent beta-thalassemia in patients aged 12 years and older. While this therapy was specifically approved for beta-thalassemia, it represents a significant advancement in the field of thalassemia treatment and suggests potential future applications for alpha thalassaemia^[11].

The gene therapy process involves collecting the patient’s own blood stem cells (the cells in bone marrow that produce all blood cells). These stem cells are then genetically modified in a laboratory to correct the defect that causes thalassemia. Before the modified cells can be returned to the patient, the person must undergo high-dose chemotherapy to remove the existing stem cells from their bone marrow. The modified stem cells are then infused back into the patient as a one-time treatment. If successful, these corrected stem cells establish themselves in the bone marrow and begin producing healthy red blood cells^[11].

This approach is being studied because it offers the potential for a cure rather than lifelong management of symptoms. However, the treatment is complex, requires significant medical infrastructure, and carries risks associated with the chemotherapy preparation phase. Research continues to refine these techniques and understand which patients might benefit most from this type of intervention.

Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplant, represents another potentially curative treatment option for severe forms of alpha thalassaemia. In this procedure, the patient receives healthy stem cells from a donor whose tissue type closely matches their own, typically a sibling. These donor stem cells replace the patient’s defective blood-producing system with a healthy one^[9].

HSCT is curative because it completely replaces the patient’s blood-forming system with that of a healthy donor. Once the transplant is successful, the patient’s body begins producing normal hemoglobin and no longer requires regular blood transfusions. However, this treatment carries significant risks, including the possibility that the new stem cells might attack the patient’s body (a condition called graft-versus-host disease), serious infections, and other complications. The procedure requires intensive medical care and a prolonged recovery period^[12].

Because of these risks, HSCT is typically considered only for patients with severe forms of alpha thalassaemia who have access to a well-matched donor and specialized medical centers with expertise in performing these transplants. The decision to pursue HSCT involves careful consideration of the risks and benefits, taking into account the patient’s current health status, age, and the severity of their disease.

Fetal Interventions for Alpha Thalassemia Major

For pregnancies affected by alpha thalassemia major, specialized fetal treatment centers are now offering innovative interventions that were not available in the past. When a fetus is diagnosed with alpha thalassemia major, it develops severe anemia before birth, which historically resulted in death either before or shortly after delivery. However, advances in fetal medicine have introduced new possibilities for treatment^[13].

Intrauterine transfusions (IUTs) involve giving blood transfusions to the fetus while still in the womb. Using ultrasound guidance, doctors can deliver healthy red blood cells directly to the fetus through the umbilical cord. This treatment helps manage the severe anemia and prevents the development of hydrops fetalis, a dangerous condition where excess fluid builds up in the fetal body. Multiple transfusions may be needed throughout the pregnancy to keep the fetus stable until delivery is possible^[13].

Even more innovative is the experimental approach of in utero stem cell transplantation for alpha thalassemia major. This involves transplanting healthy stem cells into the fetus before birth, with the goal of establishing a healthy blood-forming system before the baby is born. This approach is still being studied and is available only at a few highly specialized centers. Families considering these interventions need to receive care at specialized perinatal centers where they can make informed decisions about pursuing aggressive treatments, including the risks and benefits involved^[9][13].

Clinical Trial Phases and Research Direction

Research into new treatments for alpha thalassaemia progresses through several phases of clinical trials, each designed to answer specific questions about safety and effectiveness. Phase I trials focus primarily on safety, testing new treatments in small groups of people to identify appropriate doses and monitor for serious side effects. Phase II trials involve larger groups and begin to evaluate whether the treatment actually works to improve the condition, while also continuing to monitor safety. Phase III trials compare the new treatment directly with current standard treatments in large numbers of patients to determine if the new approach offers meaningful advantages^[9].

Current research efforts in alpha thalassaemia focus on several promising areas. Scientists are working to develop better methods for gene therapy that might be safer and more effective than current approaches. Researchers are also studying ways to improve chelation therapy to make it more convenient and reduce side effects, which could help patients adhere more consistently to this critical treatment. Studies are ongoing to better understand which patients might benefit most from stem cell transplantation and how to reduce the risks associated with this procedure.

Living Well with Alpha Thalassaemia

Beyond medical treatments, maintaining overall health and wellbeing is crucial for people living with alpha thalassaemia. A healthy lifestyle means both managing the disorder according to medical recommendations and making positive choices in daily life. The most important thing patients can do is stick to their prescribed treatment schedules, whether that involves regular transfusions, daily chelation medication, or other therapies^[14].

Nutrition plays an important role in managing alpha thalassaemia. For people with more severe forms who receive regular transfusions, limiting dietary iron may be recommended, as they already accumulate excess iron from transfusions. This means being mindful about consuming iron-rich foods like red meat, liver, and iron-fortified cereals, and avoiding iron supplements unless specifically prescribed for another condition. However, maintaining good overall nutrition with plenty of fruits, vegetables, and other nutrients remains important^[14].

Regular physical activity benefits people with alpha thalassaemia in multiple ways. Exercise helps strengthen bones, which can be affected by the disease and its treatments. It also supports heart health and improves overall energy levels and mood. While some people with severe forms may have limitations on very vigorous exercise, many can participate in moderate activities like walking, swimming, or cycling. Patients should discuss with their healthcare team what level of exercise is appropriate for their individual situation^[14].

Preventing infections is particularly important, especially for people who have had their spleen removed. Staying up to date with all recommended vaccinations, including annual flu shots, provides crucial protection. Regular handwashing, avoiding close contact with sick people when possible, and seeking prompt medical attention for any fever or signs of infection all help reduce the risk of serious complications^[15].

Attending all scheduled medical appointments allows healthcare teams to monitor for complications and adjust treatments as needed. These checkups typically include blood tests to measure hemoglobin levels, iron stores, liver function, and other important indicators. Some patients may also need periodic heart monitoring, bone density scans, or hormone level checks to screen for treatment-related complications^[16].

Most common treatment methods

• Blood transfusions
  • Regular transfusions every 3-4 weeks for alpha thalassemia major to maintain hemoglobin above 9.5 g/dL
  • Occasional transfusions for Hemoglobin H disease during infections, pregnancy, or surgery
  • Procedure takes 1-4 hours through intravenous line
  • Helps prevent severe anemia and supports normal growth and development
• Iron chelation therapy
  • Deferasirox: oral pill taken once daily
  • Deferoxamine: injection under the skin over 8-12 hours, usually overnight
  • Deferiprone: oral pill taken three times daily
  • Removes excess iron accumulated from regular blood transfusions
  • Prevents iron damage to heart, liver, and hormone-producing glands
• Folic acid supplementation
  • B vitamin that supports red blood cell production
  • Particularly beneficial for patients with Hemoglobin H disease
  • Compensates for increased folic acid use due to high bone marrow turnover
  • Usually prescribed alongside other treatments
• Gene therapy
  • CASGEVY™ (exagamglogene autotemcel) approved for transfusion-dependent beta-thalassemia in patients 12 years and older
  • Involves collecting patient’s own stem cells, genetically modifying them, and returning them after chemotherapy preparation
  • One-time treatment with potential for cure
  • Research ongoing for applications in alpha thalassaemia
• Hematopoietic stem cell transplantation
  • Bone marrow transplant from well-matched donor, typically a sibling
  • Curative treatment that replaces patient’s blood-forming system
  • Considered for severe cases with available matched donors
  • Carries risks including graft-versus-host disease and infections
• Fetal interventions
  • Intrauterine transfusions for fetuses with alpha thalassemia major
  • Experimental in utero stem cell transplantation
  • Available at specialized fetal treatment centers
  • Aims to prevent hydrops fetalis and improve survival
• Surgical procedures
  • Splenectomy (removal of spleen) in selected cases of enlarged spleen causing pain or worsening anemia
  • Requires lifelong protection against infections through vaccines and possibly daily antibiotics
  • Not routinely performed, only when benefits outweigh risks